Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

August 01, 1996; Volume 50,Issue 2
  • You have access
    Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
    I Bouchelet, Z Cohen, B Case, P Séguéla and E Hamel
    Molecular Pharmacology August 1996, 50 (2) 219-223;
  • You have access
    Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor.
    R A Nicholas, W C Watt, E R Lazarowski, Q Li and K Harden
    Molecular Pharmacology August 1996, 50 (2) 224-229;
  • You have access
    Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus.
    S R Glaum, M Hara, V P Bindokas, C C Lee, K S Polonsky, G I Bell and R J Miller
    Molecular Pharmacology August 1996, 50 (2) 230-235;
  • You have access
    Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
    T Yazaki, S Ahmad, A Chahlavi, E Zylber-Katz, N M Dean, S D Rabkin, R L Martuza and R I Glazer
    Molecular Pharmacology August 1996, 50 (2) 236-242;
  • You have access
    Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
    R Ganapathi, A Constantinou, N Kamath, G Dubyak, D Grabowski and K Krivacic
    Molecular Pharmacology August 1996, 50 (2) 243-248;
  • You have access
    Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity by genistein, a tyrosine kinase inhibitor.
    C P Tseng and A K Verma
    Molecular Pharmacology August 1996, 50 (2) 249-257;
  • You have access
    A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.
    T E Webb, D Henderson, B F King, S Wang, J Simon, A N Bateson, G Burnstock and E A Barnard
    Molecular Pharmacology August 1996, 50 (2) 258-265;
  • You have access
    Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition.
    H E Melikian, S Ramamoorthy, C G Tate and R D Blakely
    Molecular Pharmacology August 1996, 50 (2) 266-276;
  • You have access
    Characterization of hepatic nitric oxide synthase: identification as the cytokine-inducible form primarily regulated by oxidants.
    D L Duval, D R Miller, J Collier and R E Billings
    Molecular Pharmacology August 1996, 50 (2) 277-284;
  • You have access
    Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
    M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
    Molecular Pharmacology August 1996, 50 (2) 285-292;
  • You have access
    Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits.
    K M Standifer, G C Rossi and G W Pasternak
    Molecular Pharmacology August 1996, 50 (2) 293-298;
  • You have access
    Irreversible inhibition of forskolin interactions with type I adenylyl cyclase by a 6-isothiocyanate derivative of forskolin.
    E M Sutkowski, J D Robbins, W J Tang and K B Seamon
    Molecular Pharmacology August 1996, 50 (2) 299-305;
  • You have access
    Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro.
    S A Berry, M C Shah, N Khan and B L Roth
    Molecular Pharmacology August 1996, 50 (2) 306-313;
  • You have access
    A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.
    J M Coulson, D R Poyner, A Chantry, W J Irwin and S Akhtar
    Molecular Pharmacology August 1996, 50 (2) 314-325;
  • You have access
    Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9.
    S Lecoeur, C André and P H Beaune
    Molecular Pharmacology August 1996, 50 (2) 326-333;
  • You have access
    Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation.
    Y J Jeon, K H Yang, J T Pulaski and N E Kaminski
    Molecular Pharmacology August 1996, 50 (2) 334-341;
  • You have access
    Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene.
    E Hedlund, A Wyss, T Kainu, M Backlund, C Köhler, M Pelto-Huikko, J A Gustafsson and M Warner
    Molecular Pharmacology August 1996, 50 (2) 342-350;
  • You have access
    Structural requirements for G(o) activation by receptor-derived peptides: activation and modulation domains of the alpha 2-adrenergic receptor i3c region.
    S M Wade, M K Scribner, H M Dalman, J M Taylor and R R Neubig
    Molecular Pharmacology August 1996, 50 (2) 351-358;
  • You have access
    Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
    C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
    Molecular Pharmacology August 1996, 50 (2) 359-366;
  • You have access
    Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside.
    F J Azula, E S Alzola, M Conde, M Trueba, J M Macarulla and A Marino
    Molecular Pharmacology August 1996, 50 (2) 367-379;
  • You have access
    Mapping the block of a cloned human inward rectifier potassium channel by dofetilide.
    J Kiehn, B Wible, A E Lacerda and A M Brown
    Molecular Pharmacology August 1996, 50 (2) 380-387;
  • You have access
    Transport of the antiviral nucleoside analogs 3'-azido-3'-deoxythymidine and 2',3'-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes.
    S Y Yao, C E Cass and J D Young
    Molecular Pharmacology August 1996, 50 (2) 388-393;
  • You have access
    Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
    J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson
    Molecular Pharmacology August 1996, 50 (2) 394-401;
  • You have access
    A single amino acid determines differences in ethanol actions on strychnine-sensitive glycine receptors.
    M P Mascia, S J Mihic, C F Valenzuela, P R Schofield and R A Harris
    Molecular Pharmacology August 1996, 50 (2) 402-406;
  • You have access
    Alpha 2-adrenergic receptors activate phospholipase C in renal epithelial cells.
    F A Gesek
    Molecular Pharmacology August 1996, 50 (2) 407-414;
  • You have access
    Inhibition of receptor/G protein coupling by suramin analogues.
    W Beindl, T Mitterauer, M Hohenegger, A P Ijzerman, C Nanoff and M Freissmuth
    Molecular Pharmacology August 1996, 50 (2) 415-423;
  • You have access
    Receptor internalization delays m4 muscarinic acetylcholine receptor resensitization at the plasma membrane.
    G S Bogatkewitsch, W Lenz, K H Jakobs and C J Van Koppen
    Molecular Pharmacology August 1996, 50 (2) 424-429;
  • You have access
    Novel natriuretic peptide receptor/guanylyl cyclase A-selective agonist inhibits angiotensin II- and forskolin-evoked aldosterone synthesis in a human zona glomerulosa cell line.
    L J Olson, D G Lowe and J G Drewett
    Molecular Pharmacology August 1996, 50 (2) 430-435;
  • You have access
    Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
    F Schmitz, D S Pratt, M J Wu, L F Kolakowski, M Beinborn and A S Kopin
    Molecular Pharmacology August 1996, 50 (2) 436-441;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 50, Issue 2
1 Aug 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics